Real-world HO data support setmelanotide efficacy, but high valuation and capital burn keep risk/reward unattractive

What happened

Rhythm presented real-world data at the 2026 European Congress of Endocrinology showing clinically meaningful BMI reductions in 62 adults with acquired hypothalamic obesity (HO) treated with setmelanotide for 12 months in France. This adds to the positive TRANSCEND trial data and supports the HO label expansion thesis, providing further evidence of real-world effectiveness. However, the stock trades at ~$105 with a $7B market cap, deeply negative earnings, and reliance on external capital. The French real-world data come from a small sample and do not address pricing pressures or competitive dynamics. The company still posted a $149M net loss in the first nine months of 2025, and cash runway is roughly two years assuming no unexpected increases in burn. While the data incrementally support the HO opportunity, they do not reduce the substantial execution risk or the lack of margin of safety at current prices.

Implication

The real-world data reinforce the HO thesis, but the path to profitability remains uncertain. Monitor HO launch metrics, payer coverage, and expense discipline. A position only becomes attractive if HO drives sustained 30%+ revenue growth with controlled SG&A, or if the stock corrects materially.

Thesis delta

The real-world HO data incrementally de-risk the HO launch, supporting the bull case that setmelanotide can achieve meaningful uptake in acquired obesity. However, the stock's 91% run-up already prices in smooth HO execution and expansion. The fundamental risk of high cash burn, ex-U.S. pricing volatility, and dependence on later-stage trials (PWS, EMANATE) remains unchanged. The thesis shifts slightly positive on HO clinical confidence, but the valuation leaves no room for error, so the WAIT rating holds.